In response to small COVID-19 drug trials with low-quality evidence, the FDA issued a guidance statement for industry in May.21 The agency stressed the need for randomized, placebo-controlled, double-blind trials using a superiority design, defining endpoints to assess clinically meaningful aspects of the disease, and the inclusion of a broad range of participants, including patients from ethnic and racial minorities, Dr. Nikolov said. In research to find effective COVID-19 treatments, “there is a need for a multidisciplinary approach, coordinated global efforts and multi-stakeholder engagement,” he said.
You Might Also Like
Explore This IssueJanuary 2021
Also By This Author
Susan Bernstein is a freelance journalist based in Atlanta.
- Janssen Pharmaceutical Companies of Johnson & Johnson. News release: SIMPONI ARIA (golimumab) approved by the U.S. Food and Drug Administration for active polyarticular juvenile idiopathic arthritis and extension of its active psoriatic arthritis indication in patients 2 years of age and older. 2020 Sep 30.
- S. National Institutes of Health. Efficacy study of tofacitinib in pediatric JIA Population (NCT02592434). ClinicalTrials.gov. 2020 Apr 13.
- S. Food and Drug Administration. News release: FDA approves first treatment for adult onset Still’s disease, a severe and rare disease. 2020 Jun 16.
- Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2020 Aug 7. [Epub ahead of print].
- Pavelka K, Kivitz AJ, Dokoupilova E, et al. Secukinumab 150/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3‐year results from the phase 3 MEASURE 3 study. ACR Open Rheumatol. 2020 Feb;2(2):119–127.
- Deodhar A, van der Heidje D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): A randomised, placebo-controlled trial. Lancet. 2020 Jan 4;395(10217):53–64.
- Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020 May;8(5):453–460.
- D’Cruz D, Maksimowicz-McKinnon K, Oates J, et al. Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: Results from the EMBRACE study. Lupus Sci Med 2019 Apr;6(Suppl 1):A149–A150.
- S. Food and Drug Administration. First generic drug approvals. 2020 Nov 18.
- S. Food and Drug Administration Drug Safety Communication. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. 2020 Apr 24.
- Sheikh S, Scheinberg M, Wei JCC, et al. LB0012 Headline results for a phase 4, 52-week, randomised, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. Ann Rheum Dis. 2019;78(Suppl 2):266.
- S. Food and Drug Administration. Pharmacovigilance review. 2020 Jan 8.
- S. Food and Drug Administration. Drug safety-related labeling changes. 2020 Jul 8.
- S. Food and Drug Administration. News release. FDA in brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. 2019 Dec 19.
- Oberfeld B, Achanta A, Carpenter K, et al. SnapShot: COVID-19. Cell. 2020 May 14;181(4):954–954.e1.
- RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19: Preliminary report. New Engl J Med. 2020 Jul 17;NEJMoa2021436. [Epub ahead of print].
- National Institute of Allergy and Infectious Diseases. Adaptive COVID-19 treatment trial (ACTT-2) (NCT04401579). gov. 2020 Dec 2.
- Sanofi S.A. News release. Sanofi provides update on Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the U.S. 2020 Sep 1.
- Roche Group. News release: Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. 2020 Jul 29.
- Roche Group. News release: Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. 2020 Sep 18.
- S. Food and Drug Administration. COVID-19: Developing drugs and biological products for treatment or prevention: Guidance for industry. 2020 May.